** Shares of medical equipment maker Thermo Fisher TMO.N rise 1.2% to $574.94 premarket
** Co beats Q4 profit and revenue estimates on improved demand for its products and services used in developing therapies
** Posts Q4 adj. profit of $6.10 per share, beating estimates of $5.94, as per data compiled by LSEG
** Reports Q4 rev of $11.40 billion, ahead of estimates of $11.28 billion
** Co says will provide 2025 forecast on earnings call
** Stock had fallen 2% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。